TG Therapeutics TGTX Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's change in AR?
- TG Therapeutics (TGTX) reported change in AR of $86.42M in Q1 2026.
- How has TG Therapeutics's change in AR changed year-over-year?
- TG Therapeutics's change in AR increased by 41.8% year-over-year, from $60.94M to $86.42M.
- What is the long-term trend for TG Therapeutics's change in AR?
- Over 4 years (2021 to 2025), TG Therapeutics's change in AR has grown at a 235.7% compound annual growth rate (CAGR), from $1.39M to $176.44M.
- What does change in AR mean?
- The net change in the amount of money customers owe the company.
- How do you interpret change in AR?
- An increase in receivables relative to sales may indicate slower customer payments or aggressive revenue recognition.
- How does change in AR compare across companies?
- Standard metric used to calculate Days Sales Outstanding (DSO) across all industries.